|
Hutchmed (China) Limited is a commercial-stage biopharmaceutical company engaged in the research, development, manufacture, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company operates a fully integrated platform that spans discovery, development, manufacturing, and commercialization. Its business segments include the provision of professional scientific and technical support services, as well as sales, distribution, and marketing services to pharmaceutical manufacturers. Hutchmed manufactures and distributes healthcare products, including prescription drugs and consumer health products, in China. The company maintains GMP-standard manufacturing facilities in Suzhou and Shanghai, China, and has qualified drug product sites in Switzerland to support global supply. It serves markets in China, the United States, the European Union, and Japan. Notable products include FRUZAQLA (fruquintinib), ATLED (fanregratinib), and ORPATHYS (savolitinib). The company has established a licensing agreement with GSK for the KRAS-EGFR antibody-targeted therapy conjugate HMPL-A830. Hutchmed has operated in the pharmaceutical sector for over two decades. Summarised from the company's own disclosures, fiscal year ended Apr 2026 |
Industry Biotechnology | Homepage hutch-med.com |
| Sector Healthcare | IR page hutch-med.com | |
|
Tags
oncology, immunology, targeted therapies, immunotherapies, cancer treatment, drug discovery, clinical trials, pharmaceutical manufacturing, biopharmaceuticals, precision medicine, FRUZAQLA, fruquintinib, ATLED, fanregratinib, ORPATHYS, savolitinib, TAGRISSO, HMPL-A830, SANOVO, SAFFRON, SACHI, FRESCO-2, ESLIM-01, Sovleplenib
|
Press page hutch-med.com/news |
Metrics
| Valuation | |
|---|---|
| Market cap | HK$ 18.73B |
| Market cap (USD) | $ 2.387B |
| P/E | 5.18 |
| PEG | — |
| P/BV | 1.91 |
| P/S | 4.35 |
| P/OCF | -36.92 |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | 0.41% |
| Returns | |
|---|---|
| ROE | 371.5% |
| ROI | 483.3% |
| ROIC | 483.3% |
| Profit margin | 83.4% |
| Growth | |
|---|---|
| Revenue growing | No |
| Profits growing | Yes |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | — |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 0 |
| Quality score | 12.5% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Podcast Mentions
Announcements and reports published on HKEXnews, newest first, monthly and next-day returns, proxy forms and board-meeting notices included. The link opens the announcement on HKEXnews. Material events reported to the SEC on Form 8-K or 6-K, newest first. The link opens the filing itself on EDGAR. Results, director/PDMR dealings and voting-rights totals announced to the FCA's National Storage Mechanism, newest first. The link opens the announcement on the NSM. Press releases from the company's own website, newest first.
Hong Kong, Shanghai & Florham Park, NJ — Monday, November 16, 2026: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that following the contract renewal with the China National Healthcare Security Administration (“NHSA”), the updated National Reimbursement Drug List (“NRDL”) effective on January 1, 2027 will continue to include ELUNATE®, ORPATHYS® and SULANDA®. This update reflects expanded coverage for new indications, renewed agreements for existing indications, as well as continued inclusion under current multi-year agreements.
Newly Included and Renewed Indications in the Updated NRDL:
● ELUNATE® (fruquintinib) is newly included for the treatment of patients with locally advanced or metastatic renal cell carcinoma who have failed prior vascular endothelial growth factor receptor (“VEGFR”) tyrosine kinase inhibitors (“TKI”) therapy and have not received programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor therapy in the first-line setting, in combination with sintilimab injection.
— Eligible for development incentives including 7 years of US market exclusivity upon regulatory approval —
— Marks the second US FDA Orphan Drug Designation for sovleplenib, following its recent designation for primary ITP —
Hong Kong, Shanghai & Florham Park, NJ — Thursday, November 5, 2026: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the US Food and Drug Administration (“FDA”) has granted Orphan Drug Designation to sovleplenib for the treatment of autoimmune hemolytic anemia (“AIHA”). Sovleplenib is a novel, selective, oral spleen tyrosine kinase (“Syk”) inhibitor.
This marks the second Orphan Drug Designation granted by the US FDA for sovleplenib, following the designation for primary immune thrombocytopenia (“ITP”) announced in October 2026. The FDA’s Orphan Drug Designation program provides orphan status to drugs and biologics intended for the safe and effective treatment, diagnosis, or prevention of rare diseases or conditions that affect fewer than 200,000 people in the United States.
— Follows US FDA new drug application submission in September 2026, marking important global regulatory progress —
Filings supported by positive SAFFRON global Phase III data demonstrating statistically significant and clinically meaningful PFS and OS improvements —
— Data selected for ESMO 2026 Presidential Symposium and simultaneously published in The New England Journal of Medicine —
Hong Kong, Shanghai & Florham Park, NJ — Monday, November 2, 2026: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) today announces that regulatory filings for ORPATHYS® (savolitinib) in combination with TAGRISSO® (osimertinib) have been accepted for review in Europe and Japan.
In Europe, the European Medicines Agency (EMA) has validated and accepted for regulatory review the Marketing Authorization Application (MAA) submitted by AstraZeneca, seeking approval for the combination for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (“NSCLC”) whose tumors have MET overexpression or amplification, and who had disease progression on or after an epidermal growth factor receptor (“EGFR”) tyrosine kinase inhibitor (“TKI”) therapy.
— Orphan Drug Designation granted for the treatment of primary immune thrombocytopenia —
— Underscores the potential of sovleplenib to address significant unmet medical needs in patients with this rare and serious autoimmune condition —
— Eligible for development incentives including 7 years of US market exclusivity upon regulatory approval —
Hong Kong, Shanghai & Florham Park, NJ — Thursday, October 29, 2026: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the US Food and Drug Administration (“FDA”) has granted Orphan Drug Designation to sovleplenib for the treatment of primary immune thrombocytopenia (“ITP”), an autoimmune disorder that can lead to increased risk of bleeding. Sovleplenib is a novel, selective, oral spleen tyrosine kinase (“Syk”) inhibitor.
The FDA’s Orphan Drug Designation program provides orphan status to drugs and biologics intended for the safe and effective treatment, diagnosis, or prevention of rare diseases or conditions that affect fewer than 200,000 people in the United States.
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation
for Primary Immune Thrombocytopenia
— Orphan Drug Designation granted for the treatment of primary immune thrombocytopenia —
— Underscores the potential of sovleplenib to address significant unmet medical needs in patients
with this rare and serious autoimmune condition —
— Eligible for development incentives including 7 years of US market exclusivity upon regulatory approval —
HUTCHMED (China) Limited (“HUTCHMED”) today announces that the US Food and Drug Administration (“FDA”) has granted
Orphan Drug Designation to sovleplenib for the treatment of primary immune thrombocytopenia (“ІTP”), an autoimmune
disorder that can lead to increased risk of bleeding. Sovleplenib is a novel, selective, oral spleen tyrosine kinase (“Syk”)
inhibitor.
The FDA’s Orphan Drug Designation program provides orphan status to drugs and biologics intended for the safe and
effective treatment, diagnosis, or prevention of rare diseases or conditions that affect fewer than 200,000 people in the
United States. Іf approved by the FDA for the designated indication, drugs with Orphan Drug Designation are eligible for 7
years of US market exclusivity upon approval, tax credits for qualified clinical trials, user fee waivers under the Prescription
Drug User Fee Act, and specialized regulatory guidance from the FDA during clinical development.
Іn China, New Drug Applications (“NDAs”) for sovleplenib in primary ІTP and warm antibody autoimmune hemolytic
anemia are currently under regulatory review by the National Medical Products Administration (NMPA), supported by
positive data from the pivotal ESLІM-01 and ESLІM-02 trials in China, respectively.
About ITP
ІTP is an autoimmune disorder characterized by immunologic destruction of platelets and decreased platelet production.
Patients with ІTP are at increased risk of excessive bleeding and bruising.
1
ІTP is also associated with fatigue (reported in
up to 39% of adults with ІTP) and impaired quality of life.
2, 3, 4, 5, 6
The incidence of primary ІTP in adults is 3.3/100,000 adults
per year with a prevalence of 9.5 per 100,000 adults.
7
Based on this prevalence rate, approximately 110,000 patients are
estimated to be living with primary ІTP in China, in addition to 56,000 patients in the US, Germany, France, Іtaly, Spain, UK,
and Japan. Іt has been estimated that as many as 145,000 patients are living with chronic ІTP in major pharmaceutical
markets excluding China.
8
Adult ІTP is a heterogeneous disease that can persist for years, even with best available care, and treatments are
infrequently curative. Despite availability of several treatments with differing mechanisms of action, chronicity of disease
continues to be a problem. Many patients develop resistance to treatment and thereby are prone to relapse.
9
Thus, there
remains a significant population of patients who have limited sensitivity to currently available agents and are in need of
new treatments.
2
As platelet destruction in ІTP is mediated by Syk-dependent phagocytosis of FcγR-bound platelets, Syk inhibition
represents a promising approach to management of ІTP.
10
About Sovleplenib
Sovleplenib is a novel, selective inhibitor of Syk for once daily oral administration. Syk is a major component in B-cell
receptor and FcR signaling and is an established target for the treatment of multiple subtypes of B-cell lymphomas and
autoimmune disorders.
HUTCHMED currently retains all rights to sovleplenib worldwide.
About HUTCHMED
HUTCHMED (Nasdaq/AІM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. Іt is committed
to the discovery and global development and commercialization of targeted therapies and immunotherapies for the
treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house
discovery to patients around the world, with its first four medicines marketed in China, the first of which is also approved
around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow
us on LinkedІn.
Forward-Looking Statements
This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform
Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including its expectations regarding the
therapeutic potential of sovleplenib, the further clinical development for sovleplenib, its expectations as to whether any studies on sovleplenib would meet
their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Forward-looking
statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding the timing and outcome of
clinical studies and the sufficiency of clinical data to support NDA approval of sovleplenib for the treatment of patients with ІTP or other indications in China
or other jurisdictions, unexpected adverse events or safety issues; the ability of sovleplenib to meet the primary or secondary endpoint of a study, to obtain
regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential market of sovleplenib for
a targeted indication; the sufficiency of funding; HUTCHMED’s ability to successfully develop and commercialize sovleplenib. Existing and prospective
investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of
these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AІM.
HUTCHMED undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future
events or circumstances or otherwise.
Medical Information
This announcement contains information about products that may not be available in all countries, or may be available under different trademarks, for
different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement
for any prescription drugs including the ones under development.
1
Zufferey A, et al. Pathogenesis and Therapeutic Mechanisms in Іmmune Thrombocytopenia (ІTP). J. Clin. Med. 2017, 6(2), 16.
2
McMillan R, et al. Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol. 2008
Feb;83(2):150-4.
3
Snyder CF, et al. Health-related quality of life of immune thrombocytopenic purpura patients: results from a web-based survey. Curr Med Res Opin.
2008 Oct;24(10):2767-76.
4
Doobaree ІU, et al. Thromboembolism in adults with primary immune thrombocytopenia: a systematic literature review and meta-analysis. Eur J
Haematol. 2016 Oct;97(4):321-30.
5
Sarpatwari A, et al. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice
Research Database. Haematologica. 2010 Jul;95(7):1167-75.
6
Sarpatwari A, et al. Health-related lifestyle in adults and children with primary immune thrombocytopenia (ІTP). Br J Haematol. 2010 Oct;151(2):189-
91.
7
Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. Blood. 2017 May 25;129(21):2829-2835.
8
Clarivate Landscape & Forecast for Іmmune Thrombocytopenic Purpura, 2018.
9
Provan D, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv.
2019;3(22):3780-381 7.
10
Crowley MT, et al. A critical role for Syk in signal transduction and phagocytosis mediated by Fcγ receptors on macrophages. J. Exp. Med. 186(7), 1027–
1039 (1997).
3
By Order of the Board
Edith Shih Non-executive Director and Company Secretary
Hong Kong, October 29, 2026
As at the date of this announcement, the Directors of the Company are:
Chairman and Non-executive Director: Dr Dan ELDAR
Executive Directors:
Dr Weiguo SU
(Chief Executive Officer and
Chief Scientific Officer)
Mr CHENG Chig Fung, Johnny
(Acting Chief Executive Officer and
Chief Financial Officer)
Non-executive Directors:
Ms Edith SHІH
Ms Ling YANG
Independent Non-executive Directors:
Dr Renu BHATІA
(Senior and Lead Іndependent Non-executive Director)
Dr Chaohong HU
Professor TAN Shao Weng, Daniel
Mr WONG Tak Wai
1 Press Release
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation
for Primary Immune Thrombocytopenia
— Orphan Drug Designation granted for the treatment of primary immune thrombocytopenia —
— Underscores the potential of sovleplenib to address significant unmet medical needs
in patients with this rare and serious autoimmune condition —
— Eligible for development incentives including 7 years of US market exclusivity upon regulatory approval —
Hong Kong, Shanghai & Florham Park, NJ — Thursday, October 29, 2026: HUTCHMED (China) Limited
(“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the US Food and Drug Administration
(“FDA”) has granted Orphan Drug Designation to sovleplenib for the treatment of primary immune
thrombocytopenia (“ITP”), an autoimmune disorder that can lead to increased risk of bleeding. Sovleplenib is a
novel, selective, oral spleen tyrosine kinase (“Syk”) inhibitor.
The FDA’s Orphan Drug Designation program provides orphan status to drugs and biologics intended for the safe and effective treatment, diagnosis, or prevention of rare diseases or conditions that affect fewer than 200,000 people in the United States. If approved by the FDA for the designated indication, drugs with Orphan Drug Designation are eligible for 7 years of US market exclusivity upon approval, tax credits for qualified clinical trials, user fee waivers under the Prescription Drug User Fee Act, and specialized regulatory guidance from the FDA during clinical development.
In China, New Drug Applications (“NDAs”) for sovleplenib in primary ITP and warm antibody autoimmune hemolytic anemia are currently under regulatory review by the National Medical Products Administration (NMPA), supported by positive data from the pivotal ESLIM-01 and ESLIM-02 trials in China, respectively.
About ITP ITP is an autoimmune disorder characterized by immunologic destruction of platelets and decreased platelet production. Patients with ITP are at increased risk of excessive bleeding and bruising. 1 ITP is also associated with fatigue (reported in up to 39% of adults with ITP) and impaired quality of life. 2,3,4,5,6 The incidence of primary ITP in adults is 3.3/100,000 adults per year with a prevalence of 9.5 per 100,000 adults. 7 Based on this prevalence rate, approximately 110,000 patients are estimated to be living with primary ITP in China, in addition to 56,000 patients in the US, Germany, France, Italy, Spain, UK, and Japan. It has been estimated that as many as 145,000 patients are living with chronic ITP in major pharmaceutical markets excluding China. 8
Adult ITP is a heterogeneous disease that can persist for years, even with best available care, and treatments are infrequently curative. Despite availability of several treatments with differing mechanisms of action, chronicity of disease continues to be a problem. Many patients develop resistance to treatment and thereby are prone to relapse. 9 Thus, there remains a significant population of patients who have limited sensitivity to currently available agents and are in need of new treatments.
As platelet destruction in ITP is mediated by Syk-dependent phagocytosis of FcγR-bound platelets, Syk inhibition represents a promising approach to management of ITP. 10
About Sovleplenib Sovleplenib is a novel, selective inhibitor of Syk for once daily oral administration. Syk is a major component in B-cell receptor and FcR signaling and is an established target for the treatment of multiple subtypes of B-cell lymphomas and autoimmune disorders.
HUTCHMED currently retains all rights to sovleplenib worldwide.
About HUTCHMED HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first four medicines
2 marketed in China, the first of which is also approved around the world including in the US, Europe and Japan.
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, October 27, 2026: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces an expert webcast, co-hosted with Citigroup Global Markets Asia Limited (“Citigroup”) for analysts and investors, to discuss recent Phase III clinical data for savolitinib in MET-driven non-small cell lung cancer (“NSCLC”) recently presented at the European Society for Medical Oncology (ESMO) Congress 2026. This virtual webcast will take place on Thursday, November 5, 2026, at 4:30 pm HKT / 8:30 am GMT / 3:30 am EST.
The discussion will be led by Professor Yi-Long Wu, principal investigator of the SANOVO study, who will share insights on the latest clinical data and treatment strategies for MET-driven NSCLC. Dr Weiguo Su, Chief Executive Officer (presently on leave of absence) and Chief Scientific Officer of HUTCHMED, will also join the panel to discuss the development progress to date and global regulatory outlook of savolitinib in light of data from both the SANOVO study in China and the SAFFRON global study. The event will be moderated by Mr Yingqi Peng, Asia Healthcare Research Analyst from Citigroup.
Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer
HUTCHMED (China) Limited (“HUTCHMED”) today announces an expert webcast, co-hosted with Citigroup Global Markets Asia Limited (“Citigroup”) for analysts and investors, to discuss recent Phase ІІІ clinical data for savolitinib in MET-driven non-small cell lung cancer (“NSCLC”) recently presented at the European Society for Medical Oncology (ESMO) Congress 2026. This virtual webcast will take place on Thursday, November 5, 2026, at 4:30 pm HKT / 8:30 am GMT / 3:30 am EST.
The discussion will be led by Professor Yi-Long Wu, principal investigator of the SANOVO study, who will share insights on the latest clinical data and treatment strategies for MET-driven NSCLC. Dr Weiguo Su, Chief Executive Officer (presently on leave of absence) and Chief Scientific Officer of HUTCHMED, will also join the panel to discuss the development progress to date and global regulatory outlook of savolitinib in light of data from both the SANOVO study in China and the SAFFRON global study. The event will be moderated by Mr Yingqi Peng, Asia Healthcare Research Analyst from Citigroup.
The webcast will be conducted in Chinese (Putonghua) with simultaneous English interpretation. Event and registration
details will be available at
www.hutch-med.com/event.
About Savolitinib
Savolitinib is an oral, potent and highly selective MET tyrosine kinase inhibitor (“TKІ”) that has demonstrated clinical activity
in advanced solid tumors. Іt blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of
mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression.
Savolitinib is marketed in China under the brand name ORPATHYS® for the treatment of adult patients with locally advanced
or metastatic NSCLC with MET exon 14 skipping alteration, representing the first selective MET inhibitor approved in China.
Savolitinib also received a conditional approval in China for the treatment of adult patients with locally advanced or
metastatic gastric cancer or gastroesophageal junction (GC/GEJ) adenocarcinoma patients with MET amplification who
have failed at least two prior systemic treatments. Savolitinib in combination with TAGRІSSO® is approved in China for
patients with locally advanced or metastatic epidermal growth factor receptor (“EGFR”) mutation-positive non-squamous
NSCLC with MET amplification after disease progression on EGFR-TKІ therapy based on the SACHІ Phase ІІІ trial. The
combination was also granted a temporary authorization in Switzerland for the treatment of patients with locally advanced
or metastatic EGFRm NSCLC and high levels of MET overexpression or amplification who progressed on prior treatment
with TAGRІSSO®. This was based on results from the global SAVANNAH Phase ІІ trial. The global, randomized, SAFFRON
Phase ІІІ trial in the same treatment setting comparing the combination with doublet platinum-based chemotherapy
reported positive high-level results, demonstrating a statistically significant and clinically meaningful improvement in
progression-free survival (“PFS”) and overall survival (“OS”) in August 2026.
Savolitinib is being jointly developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca.
2
About SANOVO
SANOVO is a blinded, randomized, controlled Phase ІІІ trial in previously untreated patients with locally advanced or
metastatic NSCLC with activating EGFR mutations and MET overexpression in China conducted by HUTCHMED. The study
evaluates the efficacy and safety of savolitinib in combination with TAGRІSSO®
compared to TAGRІSSO®
alone, a standard-
of-care treatment option for these patients. A total of 326 treatment-naïve patients with locally advanced or metastatic
NSCLC harbouring EGFR mutations (exon 19 deletion or L858R) and MET overexpression were randomized in a 1:1 ratio to
receive TAGRІSSO®
80 mg once daily plus either savolitinib
or placebo at 300/200 mg twice daily (dosed based on body
weight).
The primary endpoint of the trial is PFS as assessed by investigators. Other endpoints include PFS assessed by an
independent review committee, OS, objective response rate, duration of response, disease control rate, time to response
and safety.
About SAFFRON SAFFRON is a randomized, open-label, multi-center, global Phase ІІІ trial studying the efficacy of savolitinib (300 mg twice daily) added to TAGRІSSO® (80 mg once daily) versus doublet platinum-based chemotherapy in 338 patients with EGFRm, locally advanced or metastatic NSCLC with MET overexpression or amplification whose disease progressed following first- or second-line treatment with TAGRІSSO®. The trial enrolled patients in 230 centers across 29 countries in North America, Europe, South America and Asia. The primary endpoint is PFS and key secondary endpoint includes OS.
Patients were prospectively selected for SAFFRON using the high MET level cut-offs identified in the SAVANNAH Phase ІІ
trial. Іn SAVANNAH, MET overexpression or amplification levels were determined by two tests: immunohistochemistry
(ІHC), which detects if cancer cells have a particular protein or marker on their surface, and fluorescence in situ hybridization
(FІSH), which detects a specific DNA sequence from cancer cells.
About HUTCHMED
HUTCHMED (Nasdaq/AІM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. Іt is committed
to the discovery and global development and commercialization of targeted therapies and immunotherapies for the
treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house
discovery to patients around the world, with its first four medicines marketed in China, the first of which is also approved
around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow
us on LinkedІn.
Forward-Looking Statements
This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform
Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including its expectations regarding the
therapeutic potential of savolitinib, the further clinical development for savolitinib, its expectations as to whether any studies on savolitinib
would meet their
primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Forward-looking
statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing
and availability of subjects meeting a study’s inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse
events or safety issues; the ability of savolitinib, including as a combination therapy, to meet the primary or secondary endpoint of a study, to obtain
regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential market of savolitinib
for a targeted indication; the sufficiency of funding; HUTCHMED’s and AstraZeneca’s ability to successfully develop and commercialize savolitinib. Іn addition, as certain studies rely on the use of other drug products such as TAGRІSSO®
as combination therapeutics with savolitinib, such risks and uncertainties include assumptions regarding the safety, efficacy, supply and continued regulatory approval of these therapeutics. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AІM. HUTCHMED undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise.
3
Medical Information
This announcement contains information about products that may not be available in all countries, or may be available under different trademarks, for
different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement
for any prescription drugs including the ones under development.
By Order of the Board
Edith Shih Non-executive Director and Company Secretary
Hong Kong, October 27, 2026
As at the date of this announcement, the Directors of the Company are:
Chairman and Non-executive Director: Dr Dan ELDAR
Executive Directors:
Dr Weiguo SU
(Chief Executive Officer and
Chief Scientific Officer)
Mr CHENG Chig Fung, Johnny
(Acting Chief Executive Officer and
Chief Financial Officer)
Non-executive Directors:
Ms Edith SHІH
Ms Ling YANG
Independent Non-executive Directors:
Dr Renu BHATІA
(Senior and Lead Іndependent Non-executive Director)
Dr Chaohong HU
Professor TAN Shao Weng, Daniel
Mr WONG Tak Wai
1 Press Release
Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, October 27, 2026: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces an expert webcast, co-hosted with Citigroup Global Markets Asia Limited (“Citigroup”) for analysts and investors, to discuss recent Phase III clinical data for savolitinib in MET-driven non-small cell lung cancer (“NSCLC”) recently presented at the European Society for Medical Oncology (ESMO) Congress 2026. This virtual webcast will take place on Thursday, November 5, 2026, at 4:30 pm HKT / 8:30 am GMT / 3:30 am EST.
The discussion will be led by Professor Yi-Long Wu, principal investigator of the SANOVO study, who will share insights on the latest clinical data and treatment strategies for MET-driven NSCLC. Dr Weiguo Su, Chief Executive Officer (presently on leave of absence) and Chief Scientific Officer of HUTCHMED, will also join the panel to discuss the development progress to date and global regulatory outlook of savolitinib in light of data from both the SANOVO study in China and the SAFFRON global study. The event will be moderated by Mr Yingqi Peng, Asia Healthcare Research Analyst from Citigroup.
The webcast will be conducted in Chinese (Putonghua) with simultaneous English interpretation. Event and registration details will be available at www.hutch-med.com/event.
About Savolitinib
Savolitinib is an oral, potent and highly selective MET tyrosine kinase inhibitor (“TKI”) that has demonstrated
clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase
pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene
amplification or protein overexpression.
Savolitinib is marketed in China under the brand name ORPATHYS ® for the treatment of adult patients with locally advanced or metastatic NSCLC with MET exon 14 skipping alteration, representing the first selective MET inhibitor approved in China. Savolitinib also received a conditional approval in China for the treatment of adult patients with locally advanced or metastatic gastric cancer or gastroesophageal junction (GC/GEJ) adenocarcinoma patients with MET amplification who have failed at least two prior systemic treatments. Savolitinib in combination with TAGRISSO ® is approved in China for patients with locally advanced or metastatic epidermal growth factor receptor (“EGFR”) mutation-positive non-squamous NSCLC with MET amplification after disease progression on EGFR-TKI therapy based on the SACHI Phase III trial. The combination was also granted a temporary authorization in Switzerland for the treatment of patients with locally advanced or metastatic EGFRm NSCLC and high levels of MET overexpression or amplification who progressed on prior treatment with TAGRISSO ® . This was based on results from the global SAVANNAH Phase II trial. The global, randomized, SAFFRON Phase III trial in the same treatment setting comparing the combination with doublet platinum-based chemotherapy reported positive high-level results, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (“PFS”) and overall survival (“OS”) in August 2026.
Savolitinib is being jointly developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca.
About SANOVO SANOVO is a blinded, randomized, controlled Phase III trial in previously untreated patients with locally advanced or metastatic NSCLC with activating EGFR mutations and MET overexpression in China conducted by HUTCHMED. The study evaluates the efficacy and safety of savolitinib in combination with TAGRISSO ® compared to TAGRISSO ® alone, a standard-of-care treatment option for these patients. A total of 326 treatment- naïve patients with locally advanced or metastatic NSCLC harbouring EGFR mutations (exon 19 deletion or L858R) and MET overexpression were randomized in a 1:1 ratio to receive TAGRISSO ® 80 mg once daily plus either savolitinib
or placebo at 300/200 mg twice daily (dosed based on body weight).
The primary endpoint of the trial is PFS as assessed by investigators. Other endpoints include PFS assessed by an independent review committee, OS, objective response rate, duration of response, disease control rate, time to response and safety.
2
About SAFFRON
SAFFRON is a randomized, open-label, multi-center, global Phase III trial studying the efficacy of savolitinib
(300 mg twice daily) added to TAGRISSO
®
(80 mg once daily) versus doublet platinum-based chemotherapy
in 338 patients with EGFRm, locally advanced or metastatic NSCLC with MET overexpression or amplification
whose disease progressed following first- or second-line treatment with TAGRISSO
®
. The trial enrolled patients
in 230 centers across 29 countries in North America, Europe, South America and Asia. The primary endpoint is
PFS and key secondary endpoint includes OS.
Patients were prospectively selected for SAFFRON using the high MET level cut-offs identified in the SAVANNAH Phase II trial. In SAVANNAH, MET overexpression or amplification levels were determined by two tests: immunohistochemistry (IHC), which detects if cancer cells have a particular protein or marker on their surface, and fluorescence in situ hybridization (FISH), which detects a specific DNA sequence from cancer cells.
About HUTCHMED HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first four medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan.
— ORPATHYS® plus TAGRISSO® reduced the risk of disease progression or death by 44% in the overall population and 55% in the high MET overexpression population in the first-line setting —
— Robust PFS gains alongside very encouraging OS clinical benefit in this treatment-naïve biomarker-selected patient population —
— Offers a potential new standard of care through an all-oral, biomarker-driven frontline strategy for MET-overexpressing, EGFR-mutated lung cancer patients —
Hong Kong, Shanghai & Florham Park, NJ — Monday, October 26, 2026: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces positive results from the SANOVO Phase III trial in China. ORPATHYS® (savolitinib) plus TAGRISSO® (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in the primary endpoint progression-free survival (“PFS”) versus TAGRISSO® alone in treatment-naïve patients with epidermal growth factor receptor-mutated (“EGFRm”) locally advanced or metastatic non-small cell lung cancer (“NSCLC”) and MET overexpression.
— ORPATHYS® plus TAGRISSO® reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO® —
— ORPATHYS® plus TAGRISSO® extended median OS by nearly 5 months —
— SAFFRON is the first global Phase III trial to show significant progression-free and overall survival benefit in this setting —
— Establishes ORPATHYS® plus TAGRISSO® as an important targeted strategy to address MET-driven resistance following progression on prior EGFR TKI treatment —
Hong Kong, Shanghai & Florham Park, NJ — Monday, October 26, 2026: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces positive results from the SAFFRON global Phase III trial. ORPATHYS® (savolitinib) plus TAGRISSO® (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival (“PFS”) and overall survival (“OS”) versus doublet platinum-based chemotherapy in patients with epidermal growth factor receptor-mutated (“EGFRm”) non-small cell lung cancer (“NSCLC”).
US$14.36 (+0.08) | HK$22.56 (+0.00) | £2.16 (+0)
AIM Rule 26
-
| AIM Rule 26
-
Number of securities in issue, securities not in public hands and significant shareholders
Description of the business
Please click here for a description of the business.
The names of the directors and biographical details
Please click here for the names of the directors and brief biographical details of each.
Directors’ responsibilities
HUTCHMED is managed by a board of directors (the "Board") which consists of two executive directors, three non-executive directors and four independent non-executive directors (one of whom is senior independent director). The Board is responsible for directing the strategic objectives of HUTCHMED and overseeing the management of the business. Directors are charged with the task of promoting the success of HUTCHMED and making decisions in the best interest of HUTCHMED. The Board, led by the Chairman, approves and monitors the Group's long-term objectives and commercial strategies, annual operating and capital expenditure budgets and business plans, evaluating the performance of HUTCHMED and supervising the management of HUTCHMED.
Board committees
The Audit Committee
The Audit Committee reviews the Group's preliminary results, interim results and annual financial statements, oversees the relationship between HUTCHMED and its external auditors, monitors and reviews the effectiveness of HUTCHMED's internal audit function in the context of HUTCHMED's overall risk management systems giving due consideration to laws and regulations and the provisions of the UK Corporate Governance Code.
The Audit Committee is chaired by Mr. Wong Tak Wai and its other member are Dr. Renu Bhatia and Dr. Chaohong Hu.
The Terms of Reference of the Audit Committee are available here .
The Remuneration Committee
The Remuneration Committee assists the Board in achieving its objective of attracting, retaining and motivating people of the highest caliber and experience needed to shape and execute strategy across the Group's substantial and diverse and international business operations. It ensures that the Group administers a fair and transparent procedure for setting remuneration policies including the assessment of the performance of Executive Directors and senior executives of the Group and determining their remuneration packages.
The Remuneration Committee is chaired by Dr. Renu Bhatia and its other members are Ms. Edith Shih and Mr. Wong Tak Wai .
The Terms of Reference of the Remuneration Committee are available here .
The Technical Committee
The Technical Committee considers from time to time matters relating to the technical aspects of research and development. It invites such executives as it deems appropriate to participate in meetings from time to time.
The Technical Committee is chaired by Dr. Chaohong Hu and its other members are Dr. Dan Eldar, Dr. Weiguo Su, Dr. Renu Bhatia and Professor Daniel Tan.
The Terms of Reference of the Technical Committee are available here .
**The Nomination Committee
**The Nomination Committee reviews the structure, size, diversity profile and skills set of the Board against its needs and makes recommendations on the composition of the Board to achieve the Group corporate strategy as well as promotes shareholder value. It makes recommendations to the Board on the appointment or re-appointment of Directors, succession planning for Directors and selection of director candidates and senior management candidates. It also assesses the independence of Independent Non-executive Directors having regard to the criteria under the applicable corporate governance code or stock exchange rules and reviews Director Nomination Policy and Board Diversity Policy.
The Nomination Committee is chaired by Dr. Renu Bhatia and its other members are Dr. Dan Eldar and Dr. Chaohong Hu.
The Terms of Reference of the Nomination Committee are available here .
The Sustainability Committee
The objectives of the Sustainability Committee is to oversee management and advise the Board on the development and implementation of the corporate social responsibility and sustainability initiatives of the Group, including reviewing the related policies and practices, and assessing and making recommendations on matters concerning the Group’s sustainability development and risks.
The Sustainability Committee is chaired by Ms. Edith Shih and its other members are Mr. Johnny Cheng and Professor Daniel Tan.
The Terms of Reference of the Sustainability Committee are available here .
Country of incorporation and main country of operation
HUTCHMED, incorporated in the Cayman Islands, is the holding company of a biopharmaceutical group with operations in China, the U.S. and Europe.
Rights of shareholders
As HUTCHMED is a Cayman Islands incorporated company, the rights of shareholders may be different from the rights of shareholders in a UK incorporated company. Such rights are regulated by the Memorandum and Articles of Association of HUTCHMED and the Companies Law and common law of the Cayman Islands.
Current constitutional documents
Please click for the Memorandum and Articles of Association .
Details of any other exchanges or trading platforms
The ordinary shares of HUTCHMED were admitted to trading on AIM regulated by the London Stock Exchange as well as on the Main Board of The Stock Exchange of Hong Kong Limited. HUTCHMED also has its securities admitted to trading on Nasdaq Stock Market in the form of American Depositary Shares.
Number of securities in issue, securities not in public hands and significant shareholders
Please click here for information on the number of ordinary shares of HUTCHMED and details of significant shareholders.
Details of any restrictions on the transfer of securities
There are no restrictions on the transfer of securities in the Company.
Number and type of securities other than AIM securities
Other than its ordinary shares, HUTCHMED has not issued any other class or type of securities. Ordinary shares of HUTCHMED constitute a single class of security, which is admitted to trading on AIM, the Main Board of The Stock Exchange of Hong Kong Limited, and Nasdaq (in the form of American Depositary Shares, each representing five ordinary shares, issued by Deutsche Bank Trust Company Americas as depositary). The American Depositary Shares are receipts representing the underlying ordinary shares and do not constitute a separate class of securities.
Annual accounts and interim reports
Please click here for access to the Company's annual accounts for the last three years and interim reports since the last annual account.
Company’s notifications
Please click here to access notifications made by the Company in the past 12 months.
Admission document and circulars
Please click here to access the Company's Admission Document dated 10 May 2006. However, please note that this document was issued well over fifteen years ago and is accordingly substantially out of date.
Please click here to access circulars sent to shareholders within the past 12 months.
Corporate governance approach
HUTCHMED has adopted and fully complies with the Hong Kong Corporate Governance Code (as set out in Appendix C1 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited).
Details of the board composition and the independence of the Directors, the role and responsibilities of the Board and its committees in delivering the Group's strategy and managing risk, the structure of Executive and Non-executive Director remuneration and its alignment with performance, its risk and controls framework, and its approach to shareholder and investor engagement, are set out in the Corporate Governance Report of HUTCHMED, available here .
Code on Takeovers and Mergers
HUTCHMED is subject to the Hong Kong Code on Takeovers and Mergers but is not subject to the UK City Code on Takeovers and Mergers or any other such legislation or code in its country of incorporation.
Advisers
Please click here to access the Company's advisers.
Last updated: August 25, 2026
This is our global website, intended for visitors seeking information on HUTCHMED’s worldwide business.
© 2026 HUTCHMED © HUTCHMED (CHINA) LIMITED
Follow Us LinkedIn Twitter WeChat
This website may use certain types of cookies and other technologies to personalize content and to show more personalized ads. By clicking “Accept All”, you understand that you are directing HUTCHMED to disclose data that may be considered personal information to third parties for these purposes. For more details on what information we collect, why we collect it and to whom we disclose it, please visit our Privacy Policy .
DenyAccept All
US$14.36 (+0.08) | HK$22.56 (+0.00) | £2.16 (+0)
Corporate Governance
-
| Corporate Governance
[Audit Committee — Terms of Reference
====================================
\
[Nomination Committee — Terms of Reference
=========================================
\
[Remuneration Committee — Terms of Reference
===========================================
\
[Sustainability Committee — Terms of Reference
=============================================
\
[Technical Committee — Terms of Reference
========================================
\
[Procedures for a Shareholder to Propose a Person for Election as a Director of the Company
==========================================================================================
\
[Board Diversity Policy
======================
\
[Director Nomination Policy
==========================
\
[Memorandum and Articles of Association
======================================
\
[Statement of Compliance with the Hong Kong Corporate Governance Code
====================================================================
\
[Anti-Bribery and Anti-Corruption Policy
=======================================
\
[Code of Ethics
==============
\
[Code of Ethics for Business Partners
====================================
\
[Policy on Personal Information Governance
=========================================
\
[Information Security Policy
===========================
\
[Shareholders Communication Policy
=================================
\
[Whistleblowing Policy
=====================
\
[AIM Rule 26
===========
\
[Confidential & Price-Sensitive Insider Information and Securities Dealing Policies
==================================================================================
\
[Interactions with Healthcare Organizations, Healthcare Professionals, Patients and Patient Organizations
========================================================================================================
\
[Quality Management System Summary
=================================
\
[Drug Safety Information Reporting Summary
=========================================
\
[Taxation Policy
===============
\
[UK Finance Act 2016 (for UK establishment)
==========================================
\
Sustainability-related Policies
[Sustainability Policy
=====================
\
[Environmental Policy
====================
\
[Health and Safety Policy
========================
\
[Human Rights Policy
===================
\
[Workforce Diversity Policy
==========================
\
[Biodiversity Policy
===================
\
[Modern Slavery and Human Trafficking Statement
==============================================
\
This is our global website, intended for visitors seeking information on HUTCHMED’s worldwide business.
© 2026 HUTCHMED © HUTCHMED (CHINA) LIMITED
Follow Us LinkedIn Twitter WeChat
This website may use certain types of cookies and other technologies to personalize content and to show more personalized ads. By clicking “Accept All”, you understand that you are directing HUTCHMED to disclose data that may be considered personal information to third parties for these purposes. For more details on what information we collect, why we collect it and to whom we disclose it, please visit our Privacy Policy .
DenyAccept All
US$14.36 (+0.08) | HK$22.56 (+0.00) | £2.16 (+0)
Information for Shareholders
-
| Information for Shareholders
The ordinary shares of the Company are listed on The Stock Exchange of Hong Kong Limited (“HKEX”), the AIM market of the London Stock Exchange ("AIM") and in the form of American depositary shares (“ADSs”) on the Nasdaq Global Select Market (“Nasdaq”). Each ADS represents ownership of five ordinary shares of the Company. Additional information and specific enquiries concerning the ADSs should be directed to the ADS Depositary at the address given on this page.
Stock Codes
| HKEX: | 13 |
| Nasdaq: | HCM |
| AIM: | HCM |
Registered Office
P.O. Box 309, Ugland House
Grand Cayman, KY1-1104
Cayman Islands
| Telephone: | +1 345 949 8066 |
| Facsimile: | +1 345 949 8080 |
Principal Place of Business
48th Floor, Cheung Kong Center
2 Queen's Road Central
Hong Kong
| Telephone: | +852 2128 1188 |
| Facsimile: | +852 2128 1778 |
Principal Executive Office
Level 18, The Metropolis Tower
10 Metropolis Drive
Hunghom, Kowloon
Hong Kong
| Telephone: | +852 2121 8200 |
| Facsimile: | +852 2121 8281 |
Principal Share Registrar
Computershare Investor Services (Jersey) Limited
13 Castle Street, St. Helier
Jersey, Channel Islands JE1 1ES
| Telephone: | +44 (0)370 707 4040 |
| Facsimile: | +44 (0)370 873 5851 |
Hong Kong Branch Share Registrar
Computershare Hong Kong Investor Services Limited
Shops 1712-1716, 17th Floor
Hopewell Centre, 183 Queen’s Road East
Wanchai, Hong Kong
| Telephone: | +852 2862 8628 |
| Facsimile: | +852 2865 0990 |
CREST Depositary
Computershare Investor Services PLC
The Pavilions
Bridgwater Road
Bristol BS99 6ZY
United Kingdom
| Telephone: | +44 (0)370 702 0000 |
| Facsimile: | +44 (0)370 703 6114 |
ADS Depositary
Deutsche Bank Trust Company Americas
60 Wall Street, New York
New York 10005
USA
| Telephone: | +1 212 250 9100 |
| Facsimile: | +1 732 544 6346 |
Shareholders Contact
Please direct enquiries to:
48th Floor, Cheung Kong Center
2 Queen's Road Central
Hong Kong
| Attn: | Ms. Edith Shih Non-executive Director & Company Secretary |
| E-mail: | [email protected] |
| Facsimile: | +852 2128 1778 |
Investor Relations Contact
Please direct enquiries to:
| E-mail: | [email protected] |
| Telephone: | +852 2121 8200 |
| Facsimile: | +852 2121 8281 |
Website Address
[Dual-listing FAQs
=================
\
[Terms of Reference & Policies
=============================
\
This is our global website, intended for visitors seeking information on HUTCHMED’s worldwide business.
© 2026 HUTCHMED © HUTCHMED (CHINA) LIMITED
Follow Us LinkedIn Twitter WeChat
This website may use certain types of cookies and other technologies to personalize content and to show more personalized ads. By clicking “Accept All”, you understand that you are directing HUTCHMED to disclose data that may be considered personal information to third parties for these purposes. For more details on what information we collect, why we collect it and to whom we disclose it, please visit our Privacy Policy .
DenyAccept All
Nasdaq:US$14.36 (+0.08) | HKEX:HK$22.56 (+0.00) | AIM:£2.16 (+0)
Listing FAQs for Shareholders
-
| Listing FAQs for Shareholders
-
How does the purchase and sale of ordinary shares, ADSs and DIs work in practice?
-
What is the conversion process between HKEX, Nasdaq and AIM?
-
Are holders of ADRs/DIs entitled to vote at HUTCHMED’s annual general meeting?
-
How can I keep up to date with latest developments at HUTCHMED?
-
Who is HUTCHMED's independent registered public accounting firm?
On which stock exchanges is HUTCHMED quoted?
HUTCHMED is listed on The Stock Exchange of Hong Kong Limited (“HKEX”) under the stock code “13” and on the Nasdaq Global Select Market (“Nasdaq”) under the ticker symbol “HCM”. It is also admitted to trading on the AIM market operated by the London Stock Exchange (“AIM”) under “HCM”.
See below “What is the conversion process between HKEX, Nasdaq and AIM? ” for details of the procedure for changing shares between the three exchanges.
What is HKEX?
The Stock Exchange of Hong Kong Limited, also known as HKEX, is the Hong Kong stock exchange. Additional information is available at www.hkexnews.hk .
What is Nasdaq?
The Nasdaq Stock Market, also known as simply Nasdaq, is an American stock exchange. It is the second-largest stock exchange by market capitalization in the world, after the New York Stock Exchange. Additional information is available at www.nasdaq.com .
What is AIM?
AIM is the London Stock Exchange's international market for growth companies and it is the most successful growth market in the world. Additional information is available at www.londonstockexchange.com .
What form does HUTCHMED’s HKEX quotation take?
HUTCHMED’s ordinary shares are traded on the HKEX in the form of ordinary shares.
What form does HUTCHMED’s AIM quotation take?
HUTCHMED’s ordinary shares are traded on AIM and trades are settled electronically through the CREST system in the form of depositary interests (“DIs”). HUTCHMED’s ordinary shares traded on AIM are held by a depositary, Computershare Investor Services PLC (“Computershare”). Computershare issues DIs representing the underlying ordinary shares on a one-for-one basis and maintains a register of DI holders. The corresponding ordinary shares are held by Computershare on trust for the holders of DIs.
What are CREST and DIs?
CREST is a paperless settlement procedure enabling securities to be evidenced other than by a certificate and transferred other than by a written instrument, so that trades can settle electronically. Securities issued by non-U.K. companies, such as the ordinary shares of HUTCHMED, cannot be directly held or transferred under the CREST system, which is why DIs are required.
A DI is a facility created to enable HUTCHMED’s ordinary shares to be delivered, held and settled under the CREST system. Each DI will be treated as one ordinary share for the purposes of determining, for example, entitlement to dividends, voting rights, participation in pre-emptive follow-on offerings and returns of capital. DIs are a common feature of the AIM market and are used by many non-U.K. AIM companies.
What form does the U.S. listing take?
HUTCHMED’s ordinary shares are traded on Nasdaq in the form of American depositary shares (“ADSs”). As a result, a portion of HUTCHMED’s ordinary shares are held by its ADS depositary bank, Deutsche Bank Trust Company Americas (“Deutsche Bank”), which ordinary shares underly the ADSs held by U.S. shareholders. The ADSs are a common feature used by non-U.S. companies on the Nasdaq Stock Market.
What is an ADS?
An ADS represents ownership of shares in a non-U.S. corporation. ADSs are quoted and traded in U.S. dollars in the U.S. securities markets. ADS dividends are paid to investors in U.S. dollars. ADSs were specifically designed to facilitate the purchase, holding and sale of non-U.S. securities by U.S. investors.
What is an ADS/Ordinary Share ratio?
This ratio reflects the number of ordinary shares that correspond to one ADS. In the case of HUTCHMED, each ADR represents five ordinary shares.
What are HUTCHMED’s CUSIP and ISIN numbers?
| Ordinary Share ISIN: Ordinary Share CUSIP: | KYG4672N1198 G4672N 119 |
| ADS ISIN: ADS CUSIP: | US44842L1035 44842L 103 |
| DI ISIN: | KYG4672N1198 (same as the Ordinary Share) |
What does a depositary do?
A depositary is an entity which facilitates cross-border trading of an issuer’s shares. Among other things, depositaries provide ADS and DI issuance and cancellation services, and associated share transfer services such as maintaining the register of ADS or DI holders, distributing dividends to ADS and DI holders, providing annual meeting services and executing corporate actions. So, in practice, Deutsche Bank and Computershare, as the depositaries, maintain records of the holders of ADSs and DIs, respectively, and manage the flow of shares between the two separate markets, essentially converting DIs into ADSs when there is demand in the U.S., and converting ADSs back into DIs when there is demand for the DIs in the U.K. This service facilitates liquidity between the two markets with the objective that any price differential between the two markets is kept to a minimum.
How does the purchase and sale of ordinary shares, ADSs and DIs work in practice?
You can buy ordinary shares, ADSs or DIs through a broker, just as you would any other Hong Kong, U.S. or U.K. security. When you instruct your broker to buy HUTCHMED’s ordinary shares on your behalf, your broker will have the option of buying ordinary shares on HKEX, ADSs on Nasdaq or DIs on AIM. Conversely, when you wish to sell your position, your broker will either sell them on HKEX, Nasdaq or AIM. Any necessary conversion of securities would first be effected in the manner described below. In any event, this would be a seamless process for shareholders. Unless shareholders particularly wish to give specific instructions in that regard (in which case they are free to do so), they will not need to be concerned with which market their shares are purchased from or sold into. Brokers will simply buy or sell in the market where there is the most liquidity at that time.
Can holders of HUTCHMED securities on HKEX, Nasdaq or AIM invest in HUTCHMED securities listed on one or both of the other stock exchanges or convert from one type of security to another?
Yes, it is permissible for holders of ordinary shares, ADSs or DIs to purchase HUTCHMED’s other securities (for example, an ADS holder may purchase DIs and/or ordinary shares through its broker) or to convert some or all of their HUTCHMED securities from ordinary shares, DIs or ADSs into one of its other listed securities. The conversion process is described in further detail below. We would advise that shareholders seek advice from their broker and/or tax adviser.
What is the conversion process between HKEX, Nasdaq and AIM?
A more detailed explanation of the steps for conversion can be found here . To enquire regarding transferring shares to be traded on AIM or HKEX, please contact the Registrar, Computershare. To enquire regarding conversion of shares into Nasdaq-traded ADSs, please contact the ADS Depositary, Deutsche Bank. Contact information is available below.
How do I contact HUTCHMED’s depositaries?
ADS Depositary Contact Information – Deutsche Bank Trust Company Americas
DR Markets Distribution
| New York: | +1 212 250 9100 |
| London: | +44 (0)20 7547 6500 |
| Hong Kong: | +852 2203 5216 |
| Email: | [email protected] |
CREST Depositary Contact Information – Computershare Investor Services PLC
The Pavilions
Bridgwater Road
Bristol BS99 6ZY
United Kingdom
| Tel: | +44 (0)370 707 4040 |
| +44 (0)370 702 0000 |
How do I contact HUTCHMED’s share registrars?
Hong Kong Share Registrar contact information:
Computershare Hong Kong Investor Services Limited
Rooms 1712-1716, 17th Floor Hopewell Centre
183 Queen’s Road East
Wanchai, Hong Kong
| Contact form: | Computershare Online |
| Tel: | +852 2862 8555 |
Principal Share Registrar contact information:
Computershare Investor Services (Jersey) Limited
13 Castle Street
St. Helier
Jersey, JE1 1ES
Channel Islands
Tel: +44 (0)370 707 4040
Are holders of ADRs/DIs entitled to vote at HUTCHMED’s annual general meeting?
Holders of ADSs/DIs may authorize HUTCHMED’s applicable depositary, Deutsche Bank or Computershare, to act as a proxy in exercising voting rights in accordance with the ADS/DI holder's directions according to the number of ordinary shares represented by their respective ADSs/DIs.
How can I keep up to date with latest developments at HUTCHMED?
You can send an email to investor relations requesting to be notified of any new updates announced here .
How do I obtain a copy of HUTCHMED’s annual report?
HUTCHMED’s annual report, interim report and other press releases can be downloaded from HUTCHMED’s website .
Who is HUTCHMED’s independent registered public accounting firm?
PriceWaterhouseCoopers.
When is HUTCHMED’s financial year end?
HUTCHMED's financial year ends on December 31.
This is our global website, intended for visitors seeking information on HUTCHMED’s worldwide business.
© 2026 HUTCHMED © HUTCHMED (CHINA) LIMITED
Follow Us LinkedIn Twitter WeChat
This website may use certain types of cookies and other technologies to personalize content and to show more personalized ads. By clicking “Accept All”, you understand that you are directing HUTCHMED to disclose data that may be considered personal information to third parties for these purposes. For more details on what information we collect, why we collect it and to whom we disclose it, please visit our Privacy Policy .
DenyAccept All
US$14.36 (+0.08) | HK$22.56 (+0.00) | £2.16 (+0)
Analyst Coverage
-
| Analyst Coverage
BofA MERRILL LYNCH
Dr. Alec W. Stranahan
+1 646 743 2109
Matthew Guggenbiller
+1 646 855 5170
BLOOMBERG
Sam Fazeli
[email protected]
BOC INTERNATIONAL
Linda LU
+852 3988 6419
Dolores Tang
+852 3988 6415
BOCOM INTERNATIONAL
Ethan Ding
+852 3766 1834
Gloria Zhuge
+852 3766 1854
CAITONG SECURITIES
Wenlu Zhang
[email protected]
CICC
Jin Zhang
[email protected]
Yaxin Liu
[email protected]
CITI
Wangbin Zhou
+852 2501 2352
John Yung
+852 2501 2790
CITIC SECURITIES
Zhu Chen
+86 21 2026 2139
Anfei Li
CHINA MERCHANTS SECURITIES
Jonah Chen, PhD
+852 3189 6354
Hongdao Chen
+852 3189 6142
CHINA SECURITIES
Juying He
+86 10 5613 5323
Qinghui Yuan
+86 10 5613 5338
Jiaao Wei
+86 10 5613 5336
CAVENDISH
Adam McCarter
+44 20 7220 0553
Mike Mitchell
+44 20 7220 0550
CLSA
Matthew Yan
+852 2600 8995
Zhijie Zhao
+852 2600 7500
CMB INTERNATIONAL
Jill Wu
+852 3900 0842
Andy Wang
+852 3657 6288
DEUTSCHE BANK
Cyrus Ng
+852 2203 6208
EASTMONEY SECURITIES
Wei He / Xiaoqian Cui
+86 21 2358 6309
GOLDMAN SACHS
Paul Choi
+1 212 902 5217
Khalil Fenina
+1 212 357 6392
Daniel Ni, Ph.D.
+1 212 902 2365
GF SECURITIES
Jiarong Luo
+86 21 3800 3671
GUOSEN SECURITIES
Xibing Chen
+86 755 8198 2939
Siyu Peng
+86 755 8198 2723
HAITONG INTERNATIONAL
Kehan Meng
[email protected]
Zhaoyi Nie
[email protected]
HSBC
Cindy Chai
+86 21 6081 3805
Linda Shu
+86 755 88983246
HUA CHUANG SECURITIES
Hao Liu
[email protected]
Jiangyao Duan
[email protected]
HUATAI SECURITIES
Wen Dai
+86 21 2897 2078
Zhongping Yuan
+86 21 2897 2228
Hang Li
+86 21 2897 2228
HUAYUAN SECURITIES
Chuang Liu
[email protected]
INDUSTRIAL SECURITIES
Yuanyuan Sun
[email protected]
Xicheng Yang
[email protected]
JEFFERIES
Clara Dong, Ph.D.
+1 212 284 2432
Jenna Li
+1 332 236 6891
Yifan Xu, Ph.D.
+1 212 778 8057
Anqi Yu, Ph.D.
+1 917 781 7082
KAIYUAN SECURITIES
Ruyi Yu
[email protected]
Yuanyuan Nie
[email protected]
MORGAN STANLEY
Jack Lin
+852 3963 3746
NORTHEAST SECURITIES
Jingcheng Wang
[email protected]
ORIENT SECURITIES
Yunfei Wu
[email protected]
Xiaoyi Fu
[email protected]
PACIFIC SECURITIES
Zimei Tan
+86 755 8368 8830
Yi Zhang
+86 21 5850 2206
PANMURE LIBERUM
Dr. Julie Simmonds
+44 20 7886 2743
Seb Jantet
+44 20 3100 2047
PING AN SECURITIES
Yin Ye
[email protected]
Mengmeng Han
[email protected]
Mengge Zhang
[email protected]
SOOCHOW SECURITIES
Guoguang Zhu
[email protected]
SOUTHWEST SECURITIES
Taimeng Tang
+86 21 6841 6017
Xiangyang Du
+86 21 6841 6017
SPDB INTERNATIONAL
Jing Yang
+852 2808 6434
Ryan Hu
+852 2808 6446
SWS RESEARCH
Wenyuan Zhou
[email protected]
Mengting Hu
+86 21 2329 7818
TOPSPERITY SECURITIES
Tielin Chen
[email protected]
Jiyang Li
[email protected]
TRINITY DELTA
Lala Gregorek
[+44 20 3637 5043](tel:+44 20 3637 5043)
Philippa Gardner
[+44 20 3637 5042](tel:+44 20 3637 5042)
UBS
Chen Chen
+86-10-5832 8201
David Guo
+86 105 832 8010
UOB Kay Hian
Carol Dou
+852 2236 6749
Sunny Chen
+852 2826 4857
WESTERN SECURITIES
Mengyuan Li
+86 15618259155
Ziyue Xu
+86 18801168784
ZHONGTAI SECURITIES
Jiaqi Zhu
[email protected]
To the best knowledge of HUTCHMED (China) Limited ("HUTCHMED"), the companies and individuals listed here provide investment coverage of HUTCHMED, including regular publication of research, estimates and investment advice in relation to HUTCHMED, its subsidiaries and affiliates. HUTCHMED accepts no responsibility for the accuracy, completeness or updating of the companies and individuals listed above, and the companies and individuals listed above are under no obligation and may decline to enter into any discussion or provide any information to any person.
This page has been prepared by HUTCHMED for information purposes only and is not intended to constitute endorsement or concurrence with the investment advice provided by the above companies and individuals, in relation to HUTCHMED, its subsidiaries or affiliates, or in relation to any other company. This page is not intended to be promotional material for services offered by HUTCHMED, its subsidiaries or its affiliates, or for the companies or individuals listed above.
Any advice, opinion or estimates, made by the companies or individuals listed above, regarding the performance of HUTCHMED, or its subsidiaries or its associates, are theirs alone and do not represent views of HUTCHMED or its management. By reference to the companies and individuals listed above, HUTCHMED does not imply endorsement or concurrence with advice, opinions or estimates regarding investment in HUTCHMED, its subsidiaries or its affiliates.
This is our global website, intended for visitors seeking information on HUTCHMED’s worldwide business.
© 2026 HUTCHMED © HUTCHMED (CHINA) LIMITED
Follow Us LinkedIn Twitter WeChat
This website may use certain types of cookies and other technologies to personalize content and to show more personalized ads. By clicking “Accept All”, you understand that you are directing HUTCHMED to disclose data that may be considered personal information to third parties for these purposes. For more details on what information we collect, why we collect it and to whom we disclose it, please visit our Privacy Policy .
DenyAccept All
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, October 21, 2026: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that further to its announcement on September 3, 2026 and following the completion of customary closing conditions including antitrust regulatory reviews, the exclusive development and license agreement between HUTCHMED Limited (a subsidiary of the Company) and a subsidiary of GSK plc (“GSK”) has closed. The agreement grants the GSK subsidiary worldwide rights excluding Mainland China, Hong Kong, Macau and Taiwan to develop and commercialize HMPL-A830.
This first-in-class Antibody-Targeted Therapy Conjugate (“ATTC”) drug candidate comprises a highly selective and potent Kirsten rat sarcoma (“KRAS”) small molecule inhibitor payload conjugated to an anti-epidermal growth factor receptor (“EGFR”) antibody. Colorectal, pancreatic and lung cancers have the highest incidence of patients with KRAS-altered tumors, who often lack safe and durable KRAS therapy.
FF301 vPage 1 of 101.2.1 Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities For the month ended:30 September 2026Status:New Submission To : Hong Kong Exchanges and Clearing Limited Name of Issuer: HUTCHMED (China) Limited Date Submitted: 02 October 2026 I. Movements in Authorised / Registered Share Capital
- Class of sharesOrdinary sharesType of sharesNot applicable Listed on the Exchange (Note 1) Yes Stock code (if listed)00013Description Number of authorised/registered sharesPar valueAuthorised/registered share capital Balance at close of preceding month1,500,000,000USD0.1USD150,000,000 Increase / decrease (-)0USD Balance at close of the month1,500,000,000USD0.1USD150,000,000 Total authorised/registered share capital at the end of the month: USD150,000,000
FF301 vPage 2 of 101.2.1 II. Movements in Issued Shares and/or Treasury Shares and Public Float Sufficiency Confirmation
- Class of sharesOrdinary sharesType of sharesNot applicable Listed on the Exchange (Note 1) Yes Stock code (if listed)00013Description Number of issued shares (excluding treasury shares) Number of treasury sharesTotal number of issued shares Balance at close of preceding month872,335,1200872,335,120 Increase / decrease (-)0 Balance at close of the month872,335,1200872,335,120 Public float sufficiency confirmation (Note 4) Pursuant to Main Board Rule 13.32D(1) or 19A.28D(1) / GEM Rule 17.37D(1) or 25.21D(1), we hereby confirm that, in relation to the class of shares as set out above, as at the close of the month: the applicable public float requirement (see below) has been complied with ✔ the applicable public float requirement (see below) has not been complied with The applicable minimum public float requirement for the class of shares as set out above pursuant to Main Board Rule 13.32B or 19A.28B / GEM Rule 17.37B or 25.21B (as the case may be) is: Applicable public float thresholdInitial Prescribed Threshold - 25% of the total number of issued shares in the class to which the listed shares belong (excluding treasury shares) Additional information
FF301 vPage 3 of 101.2.1 III. Details of Movements in Issued Shares and/or Treasury Shares (A). Share Options (under Share Option Schemes of the Issuer)
- Class of sharesOrdinary sharesType of sharesNot applicableListed on the Exchange (Note 1)Yes
Stock code (if listed)00013Description
Particulars of share option scheme
Number of share
options outstanding at
close of preceding
month
Movement during the month
Number of share
options outstanding at
close of the month
Number of new shares
issued during the month
pursuant thereto (A1)
Number of treasury
shares transferred out of
treasury during the
month pursuant thereto
(A2)
Number of shares which
may be issued or
transferred out of
treasury pursuant
thereto as at close of
the month
The total number of
shares which may be
issued or transferred out
of treasury upon
exercise of all share
options to be granted
under the scheme at
close of the month
1).
Share Option Scheme
conditionally adopted on
24/04/2015
(expired on 12/5/2026) 22,886,247 Granted0 Exercised - new shares involved0 Cancelled0 Lapsed-17,350 22,868,8970019,628,99522,868,897 General Meeting approval date (if applicable)24 April 2015 2). Share Option Scheme adopted on 12/05/2026 0 Granted0 Exercised - new shares involved0 Cancelled0 Lapsed0 000043,616,756 General Meeting approval date (if applicable)12 May 2026 Increase in issued shares (excluding treasury shares): 0Ordinary shares (AA1) Decrease in treasury shares: 0Ordinary shares (AA2) Total funds raised during the month from exercise of options: USD0 Remarks: The Share Option Scheme conditionally adopted on 24/04/2015 expired on 12/5/2026 (the "Scheme"). No further options can be granted under the Scheme, but the options previously granted may continue to be exercised until the end of their respective exercise periods.
FF301 vPage 4 of 101.2.1 (B). Warrants to Issue Shares of the IssuerNot applicable
FF301 vPage 5 of 101.2.1 (C). Convertibles (i.e. Convertible into Shares of the Issuer)Not applicable
FF301 vPage 6 of 101.2.1 (D). Any other Agreements or Arrangements to Issue Shares of the Issuer, including Options (other than Share Option Schemes)Not applicable
FF301 vPage 7 of 101.2.1 (E). Other Movements in Issued Shares and/or Treasury SharesNot applicable Total increase/ decrease (-) in issued shares (excluding treasury shares) during the month (i.e. Total of AA1 to EE1):0Ordinary shares Total increase/ decrease (-) in treasury shares during the month (i.e. Total of AA2 to EE2): 0Ordinary shares
FF301 vPage 8 of 101.2.1 IV. Information about Hong Kong Depositary Receipt (HDR) Not applicable
FF301 vPage 9 of 101.2.1 V. Confirmations Not applicable Submitted by: Edith Shih Title: Non-executive Director and Company Secretary (Director, Secretary or other Duly Authorised Officer)
FF301 vPage 10 of 101.2.1 Notes 1.The Exchange refers to The Stock Exchange of Hong Kong Limited. 2.In the case of repurchase of shares (shares repurchased and cancelled) and redemption of shares (shares redeemed and cancelled), "date of event" should be construed as "cancellation date". In the case of repurchase of shares (shares held as treasury shares), "date of event" should be construed as "date on which shares were repurchased and held by the issuer in treasury". 3.The information is required in the case of repurchase of shares (shares repurchased for cancellation but not yet cancelled) and redemption of shares (shares redeemed but not yet cancelled). Please state the number of shares repurchased or redeemed during the month or in preceding month(s) but pending cancellation as at close of the month as a negative number. 4."Initial Prescribed Threshold”, "Alternative Threshold” and "market value" have the meanings ascribed thereto under Main Board Rule 13.32A or 19A.28A / GEM Rule 17.37A or 25.21A. See also Main Board Rule 13.32D(4) or 19A.28D(4) / GEM Rule 17.37D(4) or 25.21D(4) on the basis of the public float disclosure. 5.Items (i) to (viii) are suggested forms of confirmation. The listed issuer may amend the item(s) that is/are not applicable to meet individual cases. Where the issuer has already made the relevant confirmations in a return published under Main Board Rule 13.25A / GEM Rule 17.27A in relation to the securities issued, or the treasury shares sold or transferred, no further confirmation is required to be made in this return. 6.“Identical” means in this context:
the securities are of the same nominal value with the same amount called up or paid up;
they are entitled to dividend/interest at the same rate and for the same period, so that at the next ensuing distribution, the dividend/interest payable per unit will amount to exactly the same sum (gross and net); and
they carry the same rights as to unrestricted transfer, attendance and voting at meetings and rank pari passu in all other respects.
— First-in-class KRAS-payload leveraging synchronized EGFR inhibition —
Hong Kong, Shanghai & Florham Park, NJ — Monday, September 28, 2026: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated the Phase Ia part of a global clinical trial of HMPL-A830 in patients with unresectable, advanced or metastatic solid tumors. The first patient received the first dose in China on September 24, 2026.
An Antibody-Targeted Therapy Conjugate (“ATTC”) enables tumor-specific activity of potent, cell-killing, targeted therapy payloads by leveraging antibody-guided delivery. This first-in-class ATTC drug candidate comprises a highly selective and potent Kirsten rat sarcoma (“KRAS”) small molecule inhibitor payload conjugated to an anti-epidermal growth factor receptor (“EGFR”) antibody. Colorectal, pancreatic and lung cancers have the highest incidence of patients with KRAS-altered tumors, who often lack a safe and durable KRAS therapy.
— Filing seeks approval for a biomarker-directed, all-oral treatment option for patients whose tumors have MET overexpression or amplification, after progression on an EGFR-TKI therapy —
— Application supported by SAFFRON, the first global Phase III trial to demonstrate statistically significant and clinically meaningful improvements in progression-free and overall survival in this setting —
— SAFFRON builds on evidence from the SACHI Phase III and SAVANNAH Phase II trials —
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, September 29, 2026: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that AstraZeneca has submitted a New Drug Application (“NDA”) to the US Food and Drug Administration (“FDA”) for ORPATHYS® (savolitinib) plus TAGRISSO® (osimertinib) for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (“NSCLC”) whose tumors have MET overexpression or amplification, and who had disease progression on or after an epidermal growth factor receptor (“EGFR”) tyrosine kinase inhibitor (“TKI”) therapy.
The NDA is supported by the global SAFFRON Phase III trial.
Hong Kong, Shanghai & Florham Park, NJ — Thursday, September 24, 2026: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the European Society for Medical Oncology (“ESMO”) Congress 2026, taking place on October 23-27, 2026, in Madrid, Spain.
Notably, results from two positive Phase III studies evaluating the savolitinib and osimertinib combination have been selected for oral presentations. Results from the global SAFFRON study will be featured in the Presidential Symposium session, while results from the SANOVO study in China will be presented in a Proffered Paper session, both highlighting important new clinical data. Having two Phase III studies featured as late-breaking abstracts underscores the potential of this all-oral, chemo-free combination to deliver meaningful advancements for patients with non-small cell lung cancer (“NSCLC”).
The SAFFRON Global Phase III Study has been selected for a Presidential Symposium oral presentation.
— Exclusive License for HMPL-A830, a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate (“ATTC”), which is expected to enter clinical trials in H2 2026 —
— HUTCHMED webcasts today at 4:30 p.m. HKT in Chinese (Putonghua) and at 7:30 a.m. EDT / 12:30 p.m. BST / 7:30 p.m. HKT in English —
Hong Kong, Shanghai & Florham Park, NJ — Thursday, September 3, 2026: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that its subsidiary, HUTCHMED Limited, has entered into an exclusive development and license agreement with a subsidiary of GSK plc (“GSK”), granting the GSK subsidiary worldwide rights excluding Mainland China, Hong Kong, Macau and Taiwan to develop and commercialize HMPL-A830. Clinical development will initially focus on colorectal, pancreatic and lung cancer indications. The agreement includes a US$110 million upfront payment and potential development, regulatory and commercial milestone payments, for up to a total of US$1.295 billion, and royalties on net sales.
FF301 vPage 1 of 101.2.1 Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities For the month ended:31 August 2026Status:New Submission To : Hong Kong Exchanges and Clearing Limited Name of Issuer: HUTCHMED (China) Limited Date Submitted: 01 September 2026 I. Movements in Authorised / Registered Share Capital
- Class of sharesOrdinary sharesType of sharesNot applicable Listed on the Exchange (Note 1) Yes Stock code (if listed)00013Description Number of authorised/registered sharesPar valueAuthorised/registered share capital Balance at close of preceding month1,500,000,000USD0.1USD150,000,000 Increase / decrease (-)0USD Balance at close of the month1,500,000,000USD0.1USD150,000,000 Total authorised/registered share capital at the end of the month: USD150,000,000
FF301 vPage 2 of 101.2.1 II. Movements in Issued Shares and/or Treasury Shares and Public Float Sufficiency Confirmation
- Class of sharesOrdinary sharesType of sharesNot applicable Listed on the Exchange (Note 1) Yes Stock code (if listed)00013Description Number of issued shares (excluding treasury shares) Number of treasury sharesTotal number of issued shares Balance at close of preceding month872,335,1200872,335,120 Increase / decrease (-)0 Balance at close of the month872,335,1200872,335,120 Public float sufficiency confirmation (Note 4) Pursuant to Main Board Rule 13.32D(1) or 19A.28D(1) / GEM Rule 17.37D(1) or 25.21D(1), we hereby confirm that, in relation to the class of shares as set out above, as at the close of the month: the applicable public float requirement (see below) has been complied with ✔ the applicable public float requirement (see below) has not been complied with The applicable minimum public float requirement for the class of shares as set out above pursuant to Main Board Rule 13.32B or 19A.28B / GEM Rule 17.37B or 25.21B (as the case may be) is: Applicable public float thresholdInitial Prescribed Threshold - 25% of the total number of issued shares in the class to which the listed shares belong (excluding treasury shares) Additional information
FF301 vPage 3 of 101.2.1 III. Details of Movements in Issued Shares and/or Treasury Shares (A). Share Options (under Share Option Schemes of the Issuer)
- Class of sharesOrdinary sharesType of sharesNot applicableListed on the Exchange (Note 1)Yes
Stock code (if listed)00013Description
Particulars of share option scheme
Number of share
options outstanding at
close of preceding
month
Movement during the month
Number of share
options outstanding at
close of the month
Number of new shares
issued during the month
pursuant thereto (A1)
Number of treasury
shares transferred out of
treasury during the
month pursuant thereto
(A2)
Number of shares which
may be issued or
transferred out of
treasury pursuant
thereto as at close of
the month
The total number of
shares which may be
issued or transferred out
of treasury upon
exercise of all share
options to be granted
under the scheme at
close of the month
1).
Share Option Scheme
conditionally adopted on
24/04/2015
(expired on 12/5/2026) 23,090,947 Granted0 Exercised - new shares involved0 Cancelled0 Lapsed-204,700 22,886,2470019,600,27022,886,247 General Meeting approval date (if applicable)24 April 2015 2). Share Option Scheme adopted on 12/05/2026 0 Granted0 Exercised - new shares involved0 Cancelled0 Lapsed0 000043,616,756 General Meeting approval date (if applicable)12 May 2026 Increase in issued shares (excluding treasury shares): 0Ordinary shares (AA1) Decrease in treasury shares: 0Ordinary shares (AA2) Total funds raised during the month from exercise of options: USD0 Remarks: The Share Option Scheme conditionally adopted on 24/04/2015 expired on 12/5/2026 (the "Scheme"). No further options can be granted under the Scheme, but the options previously granted may continue to be exercised until the end of their respective exercise periods.
FF301 vPage 4 of 101.2.1 (B). Warrants to Issue Shares of the IssuerNot applicable
FF301 vPage 5 of 101.2.1 (C). Convertibles (i.e. Convertible into Shares of the Issuer)Not applicable
FF301 vPage 6 of 101.2.1 (D). Any other Agreements or Arrangements to Issue Shares of the Issuer, including Options (other than Share Option Schemes)Not applicable
FF301 vPage 7 of 101.2.1 (E). Other Movements in Issued Shares and/or Treasury SharesNot applicable Total increase/ decrease (-) in issued shares (excluding treasury shares) during the month (i.e. Total of AA1 to EE1):0Ordinary shares Total increase/ decrease (-) in treasury shares during the month (i.e. Total of AA2 to EE2): 0Ordinary shares
FF301 vPage 8 of 101.2.1 IV. Information about Hong Kong Depositary Receipt (HDR) Not applicable
FF301 vPage 9 of 101.2.1 V. Confirmations Not applicable Submitted by: Edith Shih Title: Non-executive Director and Company Secretary (Director, Secretary or other Duly Authorised Officer)
FF301 vPage 10 of 101.2.1 Notes 1.The Exchange refers to The Stock Exchange of Hong Kong Limited. 2.In the case of repurchase of shares (shares repurchased and cancelled) and redemption of shares (shares redeemed and cancelled), "date of event" should be construed as "cancellation date". In the case of repurchase of shares (shares held as treasury shares), "date of event" should be construed as "date on which shares were repurchased and held by the issuer in treasury". 3.The information is required in the case of repurchase of shares (shares repurchased for cancellation but not yet cancelled) and redemption of shares (shares redeemed but not yet cancelled). Please state the number of shares repurchased or redeemed during the month or in preceding month(s) but pending cancellation as at close of the month as a negative number. 4."Initial Prescribed Threshold”, "Alternative Threshold” and "market value" have the meanings ascribed thereto under Main Board Rule 13.32A or 19A.28A / GEM Rule 17.37A or 25.21A. See also Main Board Rule 13.32D(4) or 19A.28D(4) / GEM Rule 17.37D(4) or 25.21D(4) on the basis of the public float disclosure. 5.Items (i) to (viii) are suggested forms of confirmation. The listed issuer may amend the item(s) that is/are not applicable to meet individual cases. Where the issuer has already made the relevant confirmations in a return published under Main Board Rule 13.25A / GEM Rule 17.27A in relation to the securities issued, or the treasury shares sold or transferred, no further confirmation is required to be made in this return. 6.“Identical” means in this context:
the securities are of the same nominal value with the same amount called up or paid up;
they are entitled to dividend/interest at the same rate and for the same period, so that at the next ensuing distribution, the dividend/interest payable per unit will amount to exactly the same sum (gross and net); and
they carry the same rights as to unrestricted transfer, attendance and voting at meetings and rank pari passu in all other respects.
MET-Overexpressing EGFR-mutated Lung Cancer in China
— Findings build on the established success of the global SAFFRON and China SACHI trials, extending the clinical value of the all-oral combination into the first-line setting —
This announcement is made by HUTCHMED (China) Limited (“HUTCHMED”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Іnside Іnformation Provisions under Part XІVA of the Securities and Futures Ordinance (Cap. 571).
HUTCHMED today announces positive high-level results from the SANOVO China Phase III trial in treatment-naïve patients with locally advanced or metastatic non-small cell lung cancer (“NSCLC”) whose tumors harbor epidermal growth factor receptor (“EGFR”) mutation and MET overexpression. ORPATHYS® (savolitinib) plus TAGRISSO® (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival (“PFS”) versus TAGRISSO® alone in both the high MET and intention-to-treat (“ITT”) patient populations.
—Novel, highly potent oral selective FGFR 1/2/3 inhibitor approved for patients with advanced FGFR2-altered intrahepatic cholangiocarcinoma in China —
Hong Kong, Shanghai & Florham Park, NJ — Friday, August 28, 2026: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (NDA) for fanregratinib (HMPL-453), a novel, selective, oral inhibitor targeting FGFR 1/2/3, has been granted conditional approval by the China National Medical Products Administration (“NMPA”) for the treatment of adult patients with advanced, metastatic or unresectable intrahepatic cholangiocarcinoma (“ICC”) with fibroblast growth factor receptor (“FGFR”) 2 fusion or rearrangement who have previously received systemic therapy. Fanregratinib will be marketed in China under the brand name ATLED®.
ICC is a highly aggressive malignancy arising from the intrahepatic biliary epithelium. It accounts for 8.2-15.0% of primary liver cancers, and consequently it is the second most common type after hepatocellular carcinoma.
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, August 18, 2026: HUTCHMED (China) Limited (Nasdaq/AIM: HCM; HKEX:13) (the “Company”, together with its subsidiaries, the “Group”) today provides the following update pursuant to Rule 17 Schedule 2(g) of the AIM Rules for Companies (the “AIM Rules”).
The board of directors of the Company (the “Board”) was notified by Dr Dan Eldar, Chairman and Non-executive Director of the Company, that S.D. Sight Diagnostics Ltd. (“S.D. Sight”), a company of which Dr Eldar was formerly a director, had become subject to insolvency proceedings in Israel.
As the Company understands, S.D. Sight is an Israeli private company incorporated in Tel Aviv, Israel and is a medical device company developing a platform for diagnosing blood diseases using computer vision technology. Dr Eldar was a director of S.D. Sight from 20 December 2018 to 18 March 2026. Hutchison Water Israel E.P.C Ltd, of which Dr Eldar is an executive director, made an investment of approximately 9.98% in S.D. Sight and nominated Dr Eldar as a director to the board of S.D. Sight. Neither Hutchison Water Israel E.P.C Ltd nor S.D. Sight is a member of the Group.
1
Announcement pursuant to AIM Rule 17 Schedule 2(g) Update
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, August 18, 2026: HUTCHMED (China) Limited (Nasdaq/AIM: HCM; HKEX:13) (the “Company”, together with its subsidiaries, the “Group”) today provides the following update pursuant to Rule 17 Schedule 2(g) of the AIM Rules for Companies (the “AIM Rules”).
The board of directors of the Company (the “Board”) was notified by Dr Dan Eldar, Chairman and Non-executive Director of the Company, that S.D. Sight Diagnostics Ltd. (“S.D. Sight”), a company of which Dr Eldar was formerly a director, had become subject to insolvency proceedings in Israel.
As the Company understands, S.D. Sight is an Israeli private company incorporated in Tel Aviv, Israel and is a medical device company developing a platform for diagnosing blood diseases using computer vision technology. Dr Eldar was a director of S.D. Sight from 20 December 2018 to 18 March 2026. Hutchison Water Israel E.P.C Ltd, of which Dr Eldar is an executive director, made an investment of approximately 9.98% in S.D. Sight and nominated Dr Eldar as a director to the board of S.D. Sight. Neither Hutchison Water Israel E.P.C Ltd nor S.D. Sight is a member of the Group.
Based on the information available to the Company, an application for commencement of insolvency proceedings in respect of S.D. Sight was filed on 12 April 2026, with the Tel Aviv-Jaffa District Court issuing an order for commencement of proceedings on 24 May 2026, and a trustee appointed on 28 May 2026. The insolvency proceedings remained ongoing. The outcome of the proceedings is not known to the Company as at the date of this announcement.
The amount involved in the proceedings, based on public information made available by the Insolvency Proceedings Commissioner in Israel, is approximately NIS3,057,876 (equivalent to approximately US$1,019,292).
As the commencement of the insolvency proceedings in respect of S.D. Sight and the appointment of the trustee occurred within 12 months after Dr Eldar ceased to act as a director of S.D. Sight, the above information is disclosed by the Company pursuant to Rule 17 Schedule 2(g) of the AIM Rules, as a change of information regarding Dr Eldar.
As the insolvency proceedings do not involve the Group or its businesses, the Board is of the opinion that it does not have any impact on the businesses and operations of the Group.
Save as disclosed above, there is no other information concerning the above change that needs to be brought to the attention of the shareholders of the Company.
About HUTCHMED HUTCHMED (Nasdaq/AIM: HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan.
This announcement is made by HUTCHMED (China) Limited (the “Company”, together with its subsidiaries, the “Group”)
pursuant to Rules 13.51B(2) and 13.51(2)(l) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong
Kong Limited (the “Listing Rules”).
The board of directors of the Company (the “Board”) was notified by Dr Dan Eldar, Chairman and Non-executive Director of the Company, that S.D. Sight Diagnostics Ltd. (“S.D. Sight”), a company of which Dr Eldar was formerly a director, had become subject to insolvency proceedings in Іsrael.
As the Company understands, S.D. Sight is an Іsraeli private company incorporated in Tel Aviv, Іsrael and is a medical device company developing a platform for diagnosing blood diseases using computer vision technology. Dr Eldar was a director of S.D. Sight from 20 December 2018 to 18 March 2026. Hutchison Water Іsrael E.P.C Ltd, of which Dr Eldar is an executive director, made an investment of approximately 9.98% in S.D. Sight and nominated Dr Eldar as a director to the board of S.D. Sight. Neither Hutchison Water Іsrael E.P.C Ltd nor S.D. Sight is a member of the Group.
Based on the information available to the Company, an application for commencement of insolvency proceedings in
respect of S.D. Sight was filed on 12 April 2026, with the Tel Aviv-Jaffa District Court issuing an order for commencement of
proceedings on 24 May 2026, and a trustee appointed on 28 May 2026. The insolvency proceedings remained ongoing. The
outcome of the proceedings is not known to the Company as at the date of this announcement.
The amount involved in the proceedings, based on public information made available by the Іnsolvency Proceedings
Commissioner in Іsrael, is approximately NІS3,057,876 (equivalent to approximately US$1,019,292).
As the commencement of the insolvency proceedings in respect of S.D. Sight and the appointment of the trustee occurred within 12 months after Dr Eldar ceased to act as a director of S.D. Sight, the above information is disclosed by the Company pursuant to Rules 13.51B(2) and 13.51(2)(l) of the Listing Rules, as a change of information regarding Dr Eldar.
As the insolvency proceedings do not involve the Group or its businesses, the Board is of the opinion that it does not have any impact on the businesses and operations of the Group.
Save as disclosed above, there is no other information concerning the above change that needs to be brought to the
attention of the shareholders of the Company.
2 By Order of the Board
Edith Shih Non-executive Director and Company Secretary
Hong Kong, August 18, 2026
As at the date of this announcement, the Directors of the Company are:
Chairman and Non-executive Director: Dr Dan ELDAR
Executive Directors:
Dr Weiguo SU
(Chief Executive Officer and
Chief Scientific Officer)
Mr CHENG Chig Fung, Johnny
(Acting Chief Executive Officer and Chief
Financial Officer)
Non-executive Directors:
Ms Edith SHІH
Ms Ling YANG
Independent Non-executive Directors: Dr Renu BHATІA (Senior and Lead Іndependent Non-executive Director) Dr Chaohong HU Professor TAN Shao Weng, Daniel Mr WONG Tak Wai
— SAFFRON trial results reinforce TAGRISSO® as the backbone therapy across EGFRm lung cancer —
Hong Kong, Shanghai & Florham Park, NJ — Monday, August 17, 2026: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that positive high-level results from the SAFFRON Phase III trial showed ORPATHYS® (savolitinib) plus TAGRISSO® (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival (“PFS”) and overall survival (“OS”) versus doublet platinum-based chemotherapy in patients with epidermal growth factor receptor-mutated (“EGFRm”) non-small cell lung cancer (“NSCLC”). Patients in the trial had tumors with high levels of MET overexpression or amplification and had progressed on prior treatment with TAGRISSO®.
FF301 vPage 1 of 101.2.1 Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities For the month ended:31 July 2026Status:New Submission To : Hong Kong Exchanges and Clearing Limited Name of Issuer: HUTCHMED (China) Limited Date Submitted: 03 August 2026 I. Movements in Authorised / Registered Share Capital
- Class of sharesOrdinary sharesType of sharesNot applicable Listed on the Exchange (Note 1) Yes Stock code (if listed)00013Description Number of authorised/registered sharesPar valueAuthorised/registered share capital Balance at close of preceding month1,500,000,000USD0.1USD150,000,000 Increase / decrease (-)0USD Balance at close of the month1,500,000,000USD0.1USD150,000,000 Total authorised/registered share capital at the end of the month: USD150,000,000
FF301 vPage 2 of 101.2.1 II. Movements in Issued Shares and/or Treasury Shares and Public Float Sufficiency Confirmation
- Class of sharesOrdinary sharesType of sharesNot applicable Listed on the Exchange (Note 1) Yes Stock code (if listed)00013Description Number of issued shares (excluding treasury shares) Number of treasury sharesTotal number of issued shares Balance at close of preceding month872,335,1200872,335,120 Increase / decrease (-)0 Balance at close of the month872,335,1200872,335,120 Public float sufficiency confirmation (Note 4) Pursuant to Main Board Rule 13.32D(1) or 19A.28D(1) / GEM Rule 17.37D(1) or 25.21D(1), we hereby confirm that, in relation to the class of shares as set out above, as at the close of the month: the applicable public float requirement (see below) has been complied with ✔ the applicable public float requirement (see below) has not been complied with The applicable minimum public float requirement for the class of shares as set out above pursuant to Main Board Rule 13.32B or 19A.28B / GEM Rule 17.37B or 25.21B (as the case may be) is: Applicable public float thresholdInitial Prescribed Threshold - 25% of the total number of issued shares in the class to which the listed shares belong (excluding treasury shares) Additional information
FF301 vPage 3 of 101.2.1 III. Details of Movements in Issued Shares and/or Treasury Shares (A). Share Options (under Share Option Schemes of the Issuer)
- Class of sharesOrdinary sharesType of sharesNot applicableListed on the Exchange (Note 1)Yes
Stock code (if listed)00013Description
Particulars of share option scheme
Number of share
options outstanding at
close of preceding
month
Movement during the month
Number of share
options outstanding at
close of the month
Number of new shares
issued during the month
pursuant thereto (A1)
Number of treasury
shares transferred out of
treasury during the
month pursuant thereto
(A2)
Number of shares which
may be issued or
transferred out of
treasury pursuant
thereto as at close of
the month
The total number of
shares which may be
issued or transferred out
of treasury upon
exercise of all share
options to be granted
under the scheme at
close of the month
1).
Share Option Scheme
conditionally adopted on
24/04/2015
(expired on 12/5/2026) 23,093,022 Granted0 Exercised - new shares involved0 Cancelled0 Lapsed-2,075 23,090,9470019,802,67023,090,947 General Meeting approval date (if applicable)24 April 2015 2). Share Option Scheme adopted on 12/05/2026 0 Granted0 Exercised - new shares involved0 Cancelled0 Lapsed0 000043,616,756 General Meeting approval date (if applicable)12 May 2026 Increase in issued shares (excluding treasury shares): 0Ordinary shares (AA1) Decrease in treasury shares: 0Ordinary shares (AA2) Total funds raised during the month from exercise of options: USD0 Remarks: The Share Option Scheme conditionally adopted on 24/04/2015 expired on 12/5/2026 (the "Scheme"). No further options can be granted under the Scheme, but the options previously granted may continue to be exercised until the end of their respective exercise periods.
FF301 vPage 4 of 101.2.1 (B). Warrants to Issue Shares of the IssuerNot applicable
FF301 vPage 5 of 101.2.1 (C). Convertibles (i.e. Convertible into Shares of the Issuer)Not applicable
FF301 vPage 6 of 101.2.1 (D). Any other Agreements or Arrangements to Issue Shares of the Issuer, including Options (other than Share Option Schemes)Not applicable
FF301 vPage 7 of 101.2.1 (E). Other Movements in Issued Shares and/or Treasury SharesNot applicable Total increase/ decrease (-) in issued shares (excluding treasury shares) during the month (i.e. Total of AA1 to EE1):0Ordinary shares Total increase/ decrease (-) in treasury shares during the month (i.e. Total of AA2 to EE2): 0Ordinary shares
FF301 vPage 8 of 101.2.1 IV. Information about Hong Kong Depositary Receipt (HDR) Not applicable
FF301 vPage 9 of 101.2.1 V. Confirmations Not applicable Submitted by: Edith Shih Title: Non-executive Director and Company Secretary (Director, Secretary or other Duly Authorised Officer)
FF301 vPage 10 of 101.2.1 Notes 1.The Exchange refers to The Stock Exchange of Hong Kong Limited. 2.In the case of repurchase of shares (shares repurchased and cancelled) and redemption of shares (shares redeemed and cancelled), "date of event" should be construed as "cancellation date". In the case of repurchase of shares (shares held as treasury shares), "date of event" should be construed as "date on which shares were repurchased and held by the issuer in treasury". 3.The information is required in the case of repurchase of shares (shares repurchased for cancellation but not yet cancelled) and redemption of shares (shares redeemed but not yet cancelled). Please state the number of shares repurchased or redeemed during the month or in preceding month(s) but pending cancellation as at close of the month as a negative number. 4."Initial Prescribed Threshold”, "Alternative Threshold” and "market value" have the meanings ascribed thereto under Main Board Rule 13.32A or 19A.28A / GEM Rule 17.37A or 25.21A. See also Main Board Rule 13.32D(4) or 19A.28D(4) / GEM Rule 17.37D(4) or 25.21D(4) on the basis of the public float disclosure. 5.Items (i) to (viii) are suggested forms of confirmation. The listed issuer may amend the item(s) that is/are not applicable to meet individual cases. Where the issuer has already made the relevant confirmations in a return published under Main Board Rule 13.25A / GEM Rule 17.27A in relation to the securities issued, or the treasury shares sold or transferred, no further confirmation is required to be made in this return. 6.“Identical” means in this context:
the securities are of the same nominal value with the same amount called up or paid up;
they are entitled to dividend/interest at the same rate and for the same period, so that at the next ensuing distribution, the dividend/interest payable per unit will amount to exactly the same sum (gross and net); and
they carry the same rights as to unrestricted transfer, attendance and voting at meetings and rank pari passu in all other respects.
— China product sales recovery continues led by ELUNATE® and SULANDA® with over 40% growth each —
— FRUZAQLA® ex-US sales driving growth – now approved or launched in 41 countries —
— Strong progress in ATTCs, a source of novel drug candidates with broad therapeutic potential —
Hong Kong, Shanghai & Florham Park, NJ — Thursday, July 30, 2026: HUTCHMED (China) Limited (“HUTCHMED”, the “Company” or “we”) (Nasdaq/AIM:HCM; HKEX:13) today reports its financial results for the six months ended June 30, 2026 and provides updates on key clinical and commercial developments.
All amounts are expressed in US dollars unless otherwise stated. A glossary of abbreviations is on page 36.
Global sales growth driven by China rebound and FRUZAQLA® geographical expansion
● In-market sales from key China commercial products up over 40% compared to the first half of 2025. ELUNATE® (fruquintinib in China) up 41% to $60.8 million as it expanded reimbursement coverage for endometrial cancer and was approved for kidney cancer. SULANDA® up 45% to $18.4 million, boosted by upgraded recommendation in Chinese Society of Clinical Oncology guidelines for neuroendocrine tumors.
— First selective MET inhibitor approved for patients with MET-amplified advanced gastric cancer or gastroesophageal junction adenocarcinoma in China —
Hong Kong, Shanghai & Florham Park, NJ — Thursday, July 2, 2026: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (NDA) for ORPATHYS® (savolitinib) has been granted conditional approval by the China National Medical Products Administration (“NMPA”) for the treatment of locally advanced or metastatic gastric cancer or gastroesophageal junction (GC/GEJ) adenocarcinoma patients with MET amplification who have failed at least two prior systemic treatments.
Gastric cancer remains one of the most common cancers and leading causes of cancer death in China.
FF301 vPage 1 of 101.2.1 Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities For the month ended:30 June 2026Status:New Submission To : Hong Kong Exchanges and Clearing Limited Name of Issuer: HUTCHMED (China) Limited Date Submitted: 02 July 2026 I. Movements in Authorised / Registered Share Capital
- Class of sharesOrdinary sharesType of sharesNot applicable Listed on the Exchange (Note 1) Yes Stock code (if listed)00013Description Number of authorised/registered sharesPar valueAuthorised/registered share capital Balance at close of preceding month1,500,000,000USD0.1USD150,000,000 Increase / decrease (-)0USD Balance at close of the month1,500,000,000USD0.1USD150,000,000 Total authorised/registered share capital at the end of the month: USD150,000,000
FF301 vPage 2 of 101.2.1 II. Movements in Issued Shares and/or Treasury Shares and Public Float Sufficiency Confirmation
- Class of sharesOrdinary sharesType of sharesNot applicable Listed on the Exchange (Note 1) Yes Stock code (if listed)00013Description Number of issued shares (excluding treasury shares) Number of treasury sharesTotal number of issued shares Balance at close of preceding month872,335,1200872,335,120 Increase / decrease (-)0 Balance at close of the month872,335,1200872,335,120 Public float sufficiency confirmation (Note 4) Pursuant to Main Board Rule 13.32D(1) or 19A.28D(1) / GEM Rule 17.37D(1) or 25.21D(1), we hereby confirm that, in relation to the class of shares as set out above, as at the close of the month: the applicable public float requirement (see below) has been complied with ✔ the applicable public float requirement (see below) has not been complied with The applicable minimum public float requirement for the class of shares as set out above pursuant to Main Board Rule 13.32B or 19A.28B / GEM Rule 17.37B or 25.21B (as the case may be) is: Applicable public float thresholdInitial Prescribed Threshold - 25% of the total number of issued shares in the class to which the listed shares belong (excluding treasury shares) Additional information
FF301 vPage 3 of 101.2.1 III. Details of Movements in Issued Shares and/or Treasury Shares (A). Share Options (under Share Option Schemes of the Issuer)
- Class of sharesOrdinary sharesType of sharesNot applicableListed on the Exchange (Note 1)Yes
Stock code (if listed)00013Description
Particulars of share option scheme
Number of share
options outstanding at
close of preceding
month
Movement during the month
Number of share
options outstanding at
close of the month
Number of new shares
issued during the month
pursuant thereto (A1)
Number of treasury
shares transferred out of
treasury during the
month pursuant thereto
(A2)
Number of shares which
may be issued or
transferred out of
treasury pursuant
thereto as at close of
the month
The total number of
shares which may be
issued or transferred out
of treasury upon
exercise of all share
options to be granted
under the scheme at
close of the month
1).
Share Option Scheme
conditionally adopted on
24/04/2015
(expired on 12/5/2026) 23,346,922 Granted0 Exercised - new shares involved0 Cancelled0 Lapsed-253,900 23,093,0220019,802,67023,093,022 General Meeting approval date (if applicable)24 April 2015 2). Share Option Scheme adopted on 12/05/2026 0 Granted0 Exercised - new shares involved0 Cancelled0 Lapsed0 000043,616,756 General Meeting approval date (if applicable)12 May 2026 Increase in issued shares (excluding treasury shares): 0Ordinary shares (AA1) Decrease in treasury shares: 0Ordinary shares (AA2) Total funds raised during the month from exercise of options: USD0 Remarks: The Share Option Scheme conditionally adopted on 24/04/2015 expired on 12/5/2026 (the "Scheme"). No further options can be granted under the Scheme, but the options previously granted may continue to be exercised until the end of their respective exercise periods.
FF301 vPage 4 of 101.2.1 (B). Warrants to Issue Shares of the IssuerNot applicable
FF301 vPage 5 of 101.2.1 (C). Convertibles (i.e. Convertible into Shares of the Issuer)Not applicable
FF301 vPage 6 of 101.2.1 (D). Any other Agreements or Arrangements to Issue Shares of the Issuer, including Options (other than Share Option Schemes)Not applicable
FF301 vPage 7 of 101.2.1 (E). Other Movements in Issued Shares and/or Treasury SharesNot applicable Total increase/ decrease (-) in issued shares (excluding treasury shares) during the month (i.e. Total of AA1 to EE1):0Ordinary shares Total increase/ decrease (-) in treasury shares during the month (i.e. Total of AA2 to EE2): 0Ordinary shares
FF301 vPage 8 of 101.2.1 IV. Information about Hong Kong Depositary Receipt (HDR) Not applicable
FF301 vPage 9 of 101.2.1 V. Confirmations Not applicable Submitted by: Edith Shih Title: Non-executive Director and Company Secretary (Director, Secretary or other Duly Authorised Officer)
FF301 vPage 10 of 101.2.1 Notes 1.The Exchange refers to The Stock Exchange of Hong Kong Limited. 2.In the case of repurchase of shares (shares repurchased and cancelled) and redemption of shares (shares redeemed and cancelled), "date of event" should be construed as "cancellation date". In the case of repurchase of shares (shares held as treasury shares), "date of event" should be construed as "date on which shares were repurchased and held by the issuer in treasury". 3.The information is required in the case of repurchase of shares (shares repurchased for cancellation but not yet cancelled) and redemption of shares (shares redeemed but not yet cancelled). Please state the number of shares repurchased or redeemed during the month or in preceding month(s) but pending cancellation as at close of the month as a negative number. 4."Initial Prescribed Threshold”, "Alternative Threshold” and "market value" have the meanings ascribed thereto under Main Board Rule 13.32A or 19A.28A / GEM Rule 17.37A or 25.21A. See also Main Board Rule 13.32D(4) or 19A.28D(4) / GEM Rule 17.37D(4) or 25.21D(4) on the basis of the public float disclosure. 5.Items (i) to (viii) are suggested forms of confirmation. The listed issuer may amend the item(s) that is/are not applicable to meet individual cases. Where the issuer has already made the relevant confirmations in a return published under Main Board Rule 13.25A / GEM Rule 17.27A in relation to the securities issued, or the treasury shares sold or transferred, no further confirmation is required to be made in this return. 6.“Identical” means in this context:
the securities are of the same nominal value with the same amount called up or paid up;
they are entitled to dividend/interest at the same rate and for the same period, so that at the next ensuing distribution, the dividend/interest payable per unit will amount to exactly the same sum (gross and net); and
they carry the same rights as to unrestricted transfer, attendance and voting at meetings and rank pari passu in all other respects.
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, June 30, 2026: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will announce its interim results for the six months ended June 30, 2026 on Thursday, July 30, 2026 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong Time (HKT).
HUTCHMED management will host two webcast presentations for analysts and investors to discuss the interim results, followed by Q&A sessions. The English webcast will be held on Thursday, July 30, 2026, at 8:00 am EDT / 1:00 pm BST / 8:00 pm HKT. The Chinese (Putonghua) webcast will be held at 8:30 am HKT on Friday, July 31, 2026 (1:30 am BST / 8:30 pm EDT on Thursday, July 30, 2026).
Both webcasts will be available live via the company website at www.hutch-med.com/event/. The presentation will be available to download shortly before the webcast begins. A replay will also be available on the website shortly after the event.
About HUTCHMED
HUTCHMED (Nasdaq/AIM: HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company.
HUTCHMED to Announce 2026 Half-Year Financial Results
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, June 30, 2026: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) will announce its interim results for the six months ended June 30, 2026 on Thursday, July 30, 2026 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong Time (HKT).
HUTCHMED management will host two webcast presentations for analysts and investors to discuss the interim results, followed by Q&A sessions. The English webcast will be held on Thursday, July 30, 2026, at 8:00 am EDT / 1:00 pm BST / 8:00 pm HKT. The Chinese (Putonghua) webcast will be held at 8:30 am HKT on Friday, July 31, 2026 (1:30 am BST / 8:30 pm EDT on Thursday, July 30, 2026).
Both webcasts will be available live via the company website at www.hutch-med.com/event/. The presentation will be available to download shortly before the webcast begins. A replay will also be available on the website shortly after the event.
About HUTCHMED HUTCHMED (Nasdaq/AIM: HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan.
The board of directors (the “Board”) of HUTCHMED (China) Limited (the “Company”) announces that a meeting of the Board will be held on Thursday, July 30, 2026 for the purpose of, inter alia, approving the interim results of the Company and its subsidiaries for the six months ended June 30, 2026 and its publication at 7:00 pm (Hong Kong Time) on the same day.
Subsequent to approval and publication, the management of the Company will conduct an English webcast presentation with Q&A at 8:00 pm (Hong Kong Time) on the same day. The Chinese (Putonghua) webcast will be held at 8:30 am (Hong Kong Time) on Friday, July 31, 2026. Both webcasts will be available live via the website of the Company at www.hutch- med.com/event/. The presentation will be available to download shortly before the webcast begins. A replay will also be available on the website shortly after the event.
By Order of the Board
Edith Shih Non-executive Director and Company Secretary
Hong Kong, June 30, 2026
As at the date of this announcement, the Directors of the Company are:
Chairman and Non-executive Director: Dr Dan ELDAR
Executive Directors:
Dr Weiguo SU
(Chief Executive Officer and
Chief Scientific Officer)
Mr CHENG Chig Fung, Johnny
(Acting Chief Executive Officer and Chief
Financial Officer)
Non-executive Directors:
Ms Edith SHІH
Ms Ling YANG
Independent Non-executive Directors: Dr Renu BHATІA (Senior and Lead Іndependent Non-executive Director) Dr Chaohong HU Professor TAN Shao Weng, Daniel Mr WONG Tak Wai
Hong Kong, Shanghai, & Florham Park, NJ — Monday, June 29, 2026: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX: 13) announces the following blocklisting six monthly return:
1.
Name of applicant:
2.
Name of scheme:
Share Option Scheme conditionally adopted by HUTCHMED in 2015 (“2015 HUTCHMED Share Option Scheme”)
Share Option Scheme adopted by HUTCHMED in 2026 (“2026 HUTCHMED Share Option Scheme”)
3.
Period of return:
From December 29, 2025 to June 28, 2026
4.
Balance under scheme from previous return:
(a)
2015 HUTCHMED Share Option Scheme: 45,775,868 ordinary shares of US$0.1 each
(b)
2026 HUTCHMED Share Option Scheme: Nil
5.
The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return:
(a)
2015 HUTCHMED Share Option Scheme: Nil
(b)
2026 HUTCHMED Share Option Scheme: 43,616,756 ordinary shares of US$0.1 each
6.
Number of securities issued/allotted under scheme during period:
(a)
2015 HUTCHMED Share Option Scheme: 7,500
(b)
2026 HUTCHMED Share Option Scheme: Nil
7.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Hutchmed (China) Limited
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
